Insider · CIK 0001741836

DANSEY ROGER D

Reports to the SEC for 5 companies · PLYMOUTH MEETING, PA

sec.gov

Transactions

Companies

Filings

CIK

0001741836

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-05-20	INOINOVIO PHARMACEUTICALS, INC. · Common Stock OptionsA Award	Director	AAward	+41.8K sh	—	—	41,800
2026-05-20	INOINOVIO PHARMACEUTICALS, INC. · Restricted Stock UnitA Award	Director	AAward	+34.2K sh	—	—	34,200
2026-05-15	NRIXNurix Therapeutics, Inc. · Director Stock Option (right to buy)A Award	Director	AAward	+31.3K sh	—	—	31,250
2026-01-02	BCYCBICYCLE THERAPEUTICS PLCA Award	Director	AAward	+3,032 sh	—	—	15,532
2026-01-02	BCYCBICYCLE THERAPEUTICS PLC · Stock Option (right to buy)A Award	Director	AAward	+6,065 sh	—	—	6,065
2025-11-06	NRIXNurix Therapeutics, Inc. · Director Stock Option (right to buy)A Award	Director	AAward	+50K sh	—	—	50,000
2025-09-08	BCYCBICYCLE THERAPEUTICS PLCA Award	Director	AAward	+12.5K sh	—	—	12,500
2025-09-08	BCYCBICYCLE THERAPEUTICS PLC · Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2025-06-20	Kronos Bio, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−68K sh	—	—	0
2025-06-20	Kronos Bio, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−5,868 sh	—	—	0
2025-06-20	Kronos Bio, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−34K sh	—	—	0
2025-05-21	INOINOVIO PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+2,167 sh	—	—	8,916
2025-05-21	INOINOVIO PHARMACEUTICALS, INC. · Restricted Stock UnitM Exercise/Conversion	Director	MExercise/Conversion	−2,167 sh	—	—	0
2024-06-25	Kronos Bio, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+34K sh	—	—	34,000
2024-05-21	INOINOVIO PHARMACEUTICALS, INC. · Common Stock OptionsA Award	Director	AAward	+2,917 sh	—	—	2,917
2024-05-21	INOINOVIO PHARMACEUTICALS, INC. · Restricted Stock UnitA Award	Director	AAward	+2,167 sh	—	—	2,167
2024-05-15	INOINOVIO PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+2,166 sh	—	—	6,749
2024-05-15	INOINOVIO PHARMACEUTICALS, INC. · Restricted Stock UnitM Exercise/Conversion	Director	MExercise/Conversion	−2,166 sh	—	—	0
2024-05-13	INOINOVIO PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+1,000 sh	—	—	4,583
2024-05-13	INOINOVIO PHARMACEUTICALS, INC. · Restricted Stock UnitM Exercise/Conversion	Director	MExercise/Conversion	−1,000 sh	—	—	0
2023-12-14	Seagen Inc.D Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−38.3K sh	$229.00	−$8.78M	0
2023-12-14	Seagen Inc.Stock Options (Right to Buy)D Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−6,140 sh	—	—	0
2023-12-14	Seagen Inc.Stock Options (Right to Buy)D Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−1,333 sh	—	—	0
2023-12-14	Seagen Inc.Stock Options (Right to Buy)D Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−18.1K sh	—	—	0
2023-12-14	Seagen Inc.Stock Options (Right to Buy)D Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−636 sh	—	—	0
2023-12-14	Seagen Inc.Stock Options (Right to Buy)D Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−32.1K sh	—	—	0
2023-12-14	Seagen Inc.Stock Options (Right to Buy)D Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−642 sh	—	—	0
2023-12-14	Seagen Inc.Stock Options (Right to Buy)D Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−41.3K sh	—	—	0
2023-12-14	Seagen Inc.Stock Options (Right to Buy)D Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−154K sh	—	—	0
2023-12-14	Seagen Inc.Restricted Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−3,298 sh	—	—	0
2023-12-14	Seagen Inc.Restricted Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−8,586 sh	—	—	0
2023-12-14	Seagen Inc.Restricted Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−33.5K sh	—	—	0
2023-12-14	Seagen Inc.Restricted Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−2,260 sh	—	—	0
2023-12-14	Seagen Inc.Restricted Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−25.7K sh	—	—	0
2023-12-14	Seagen Inc.Performance Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−4,756 sh	—	—	0
2023-12-14	Seagen Inc.Performance Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−11.9K sh	—	—	0
2023-12-14	Seagen Inc.Performance Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−1,717 sh	—	—	0
2023-12-14	Seagen Inc.Performance Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−10.2K sh	—	—	0
2023-12-14	Seagen Inc.Performance Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−16.5K sh	—	—	0
2023-12-14	Seagen Inc.Performance Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−41.2K sh	—	—	0
2023-12-14	Seagen Inc.Performance Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−4,291 sh	—	—	0
2023-12-14	Seagen Inc.Performance Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−2,575 sh	—	—	0
2023-12-14	Seagen Inc.Performance Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−4,980 sh	—	—	0
2023-12-14	Seagen Inc.Performance Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−13.3K sh	—	—	0
2023-12-14	Seagen Inc.Performance Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−1,827 sh	—	—	0
2023-12-14	Seagen Inc.Performance Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−3,432 sh	—	—	0
2023-12-14	Seagen Inc.Performance Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−8,582 sh	—	—	0
2023-12-14	Seagen Inc.Performance Stock UnitsD Disposition to Issuer	President, R&D & CMO	DDisposition to Issuer	−5,149 sh	—	—	0
2023-09-21	Seagen Inc.S Sale	President, R&D & CMO	SSale	−71 sh	$206.50	−$14.7K	116,677
2023-08-31	Seagen Inc.S Sale	President, R&D & CMO	SSale	−4,029 sh	$206.97	−$834K	111,768

Recent filings

Accepted (ET)
May 214
DANSEY ROGER D0001741836-26-000005
SEC(opens sec.gov)
May 154
DANSEY ROGER D0001741836-26-000004
SEC(opens sec.gov)
Jan 64
DANSEY ROGER D0001741836-26-000002
SEC(opens sec.gov)
Nov 104
DANSEY ROGER D0001741836-25-000009
SEC(opens sec.gov)
Sep 104
DANSEY ROGER D0001415889-25-024098
SEC(opens sec.gov)
Jun 204
DANSEY ROGER D0001415889-25-017826
SEC(opens sec.gov)
May 214
DANSEY ROGER D0001055726-25-000034
SEC(opens sec.gov)
Jun 264
DANSEY ROGER D0001415889-24-018238
SEC(opens sec.gov)
May 224
DANSEY ROGER D0001055726-24-000035
SEC(opens sec.gov)
May 164
DANSEY ROGER D0001055726-24-000025
SEC(opens sec.gov)
May 134
DANSEY ROGER D0001055726-24-000023
SEC(opens sec.gov)

Companies

Address

660 W. GERMANTOWN PIKE SUITE 110

PLYMOUTH MEETING, PA, 19462